Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Menarini Group
This Phase Ib study will investigate the safety and anti-tumor activity of daily oral doses MEN1611 in combination with Trastuzumab with/without Fulvestrant in female and male patients affected by advanced or metastatic HER2-positive breast cancer. Fulvestrant will be added to the post-menopausal patients with hormone-sensitive disease.
MEN1611 is an investigational drug which blocks a protein called PI3K (phosphoinositide 3-kinase) involved in cancer cells growth. The Maximum Tolerated Dose (MTD) of MEN1611 given as single agent was assessed in a phase I trial in patients with advanced solid tumors.
This Phase IB will start with a dose escalation part (Step 1) to identify the MTD of MEN1611 given in combination with Trastuzumab with/without Fulvestrant.
The study will continue with a cohort expansion (Step 2) to investigate the anti-tumor activity of the selected MEN1611 dose level considered to be tolerable by a Safety Review Committee.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed invasive adenocarcinoma of the breast
Known HER2+ breast cancer
Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample
\> 2 lines of anti-HER2 based regimens with at least 1 regimen with trastuzumab
Radiological documented evidence of progressive disease
Life expectancy ≥ 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
You may not be if
Previous treatment with PI3K inhibitors
Brain metastases untreated, unless treated \> 4 weeks and only if clinically stable and not receiving corticosteroids
History of clinically significant bowel disease
≥ grade 2 diarrhoea
History of significant, uncontrolled, or active cardiovascular disease
Any serious and/or unstable pre-existing psychiatric or neurologic illness or other conditions that could interfere with patient's safety
Not controlled diabetes mellitus (glycated haemoglobin \[HbA1c\] \>7%) and fasting plasma glucose \>126 mg/dL
Concurrent chronic treatment with steroids, as immunosuppressant, or another immunosuppressive agent
Clareo Health | MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
